INNOVIVA, INC. Lease, Cost
INNOVIVA, INC. (INVA) reported Lease, Cost of $554.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-05
- INNOVIVA, INC. lease, cost for the quarter ending 2026-06-30 was $554.00K, a 81.64% increase year-over-year.
- INNOVIVA, INC. lease, cost for the quarter ending 2026-03-31 was $554.00K, a 82.24% increase year-over-year.
- INNOVIVA, INC. lease, cost for the quarter ending 2025-12-31 was $605.00K, a 90.25% increase year-over-year.
- INNOVIVA, INC. lease, cost for the quarter ending 2025-09-30 was $301.00K, a 1.35% increase year-over-year.
- INNOVIVA, INC. lease, cost for fiscal 2025 was $1.51M, a 24.79% increase from fiscal 2024.
- INNOVIVA, INC. lease, cost for fiscal 2024 was $1.21M, a 24.92% decline from fiscal 2023.
- INNOVIVA, INC. lease, cost for fiscal 2023 was $1.62M, a 7.07% decline from fiscal 2022.
- INNOVIVA, INC. lease, cost for fiscal 2022 was $1.74M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $554.00K 10-Q · filed 2026-08-05 | $1.11M 10-Q · filed 2026-08-05 | $1.71M derived: sum of 3 quarters · filed 2026-08-05 | $2.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $554.00K 10-Q · filed 2026-05-06 | $1.16M derived: sum of 2 quarters · filed 2026-05-06 | $1.46M derived: sum of 3 quarters · filed 2026-05-06 | $1.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $906.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.21M derived: sum of 3 quarters · filed 2026-08-05 | $1.51M 10-K · filed 2026-02-25 |
| 2025-09-30 | $301.00K 10-Q · filed 2025-11-05 | $606.00K derived: sum of 2 quarters · filed 2026-08-05 | $910.00K 10-Q · filed 2025-11-05 | $1.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $305.00K 10-Q · filed 2026-08-05 | $609.00K 10-Q · filed 2026-08-05 | $927.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $304.00K 10-Q · filed 2026-05-06 | $622.00K derived: sum of 2 quarters · filed 2026-05-06 | $919.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.21M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $615.00K derived: sum of 2 quarters · filed 2026-02-25 | $902.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.21M 10-K · filed 2026-02-25 |
| 2024-09-30 | $297.00K 10-Q · filed 2025-11-05 | $584.00K derived: sum of 2 quarters · filed 2025-11-05 | $896.00K 10-Q · filed 2025-11-05 | $1.30M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $287.00K 10-Q · filed 2025-08-06 | $608.00K 10-Q · filed 2025-08-06 | $1.00M derived: sum of 3 quarters · filed 2026-02-25 | $1.41M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $321.00K 10-Q · filed 2025-05-07 | $714.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.12M derived: sum of 3 quarters · filed 2026-02-25 | $1.53M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $393.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $803.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.21M derived: sum of 3 quarters · filed 2026-02-25 | $1.62M 10-K · filed 2026-02-25 |
| 2023-09-30 | $410.00K 10-Q · filed 2024-11-06 | $819.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.22M 10-Q · filed 2024-11-06 | $1.75M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $409.00K 10-Q · filed 2024-07-31 | $814.00K 10-Q · filed 2024-07-31 | $1.34M derived: sum of 3 quarters · filed 2025-02-26 | $2.02M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $405.00K 10-Q · filed 2024-05-08 | $934.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.61M derived: sum of 3 quarters · filed 2025-02-26 | |
| 2022-12-31 | $529.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.20M derived: sum of 2 quarters · filed 2025-02-26 | $1.74M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $675.00K 10-Q · filed 2023-11-01 | $1.21M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |